Clinical Observations on Associations Between the UGT1A1 Genotype and Severe Toxicity of Irinotecan

A Systemic Analysis of S-1 Regimens for Treatment of Patients with Colon Cancer

(2014) En Zhang et al.   Asian Pacific Journal of Cancer Prevention

Efficacy and Safety of Raltitrexed Combinations with Uracil-Tegafur or Mitomycin C as Salvage Treatment in Advanced Colorectal Cancer Patients: A Multicenter Study of Anatolian Society of Medical Oncology (ASMO)

(2014) Oktay Bozkurt et al.   Asian Pacific Journal of Cancer Prevention

Xeliri Plus Bevacizumab Compared with Folfiri Plus Bevacizumab as First-Line Setting in Patients with Metastatic Colorectal Cancer: Experiences at Two-Institutions

(2013) Kazim Uygun et al.   Asian Pacific Journal of Cancer Prevention

Phase II Study of Pemetrexed as Second or Third Line Combined Chemotherapy in Patients with Colorectal Cancer

(2013) Xue-Yan Wu et al.   Asian Pacific Journal of Cancer Prevention

Phase II Study on Pemetrexed-based Chemotherapy in Treating Patients with Metastatic Gastric Cancer not Responding to Prior Palliative Chemotherapy

(2013) Guo-Li Wei et al.   Asian Pacific Journal of Cancer Prevention

Dose-dependent association between UGT1A1∗28 polymorphism and irinotecan-induced diarrhoea: A meta-analysis

(2010) Zhe-Yi Hu et al.   EUROPEAN JOURNAL OF CANCER

Recommendations from the EGAPP Working Group: can UGT1A1 genotyping reduce morbidity and mortality in patients with metastatic colorectal cancer treated with irinotecan?

(2009)   GENETICS IN MEDICINE

Pharmacokinetic and pharmacogenetic determinants of the activity and toxicity of irinotecan in metastatic colorectal cancer patients

(2008) E Rouits et al.   BRITISH JOURNAL OF CANCER

Re: UGT1A1*28 Genotype and Irinotecan-Induced Neutropenia: Dose Matters

(2008) Wataru Ichikawa et al.   JNCI-Journal of the National Cancer Institute